Spectrum of Serum Sodium Disturbances in Patients With Non-sellar/Suprasellar Supratentorial Tumors
1 other identifier
observational
173
0 countries
N/A
Brief Summary
This study was designed to quantify the incidence of hyponatremia in patients of supratentorial/supra-sellar lesions and observe their effect on neurological morbidity and mortality.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Dec 2013
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 15, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 30, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
April 30, 2014
CompletedFirst Submitted
Initial submission to the registry
June 14, 2018
CompletedFirst Posted
Study publicly available on registry
June 26, 2018
CompletedJune 26, 2018
June 1, 2018
5 months
June 14, 2018
June 25, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Mortality
To observe relationship between hyponatremia in supratentorial tumor patients and in-hospital mortality.
From date of admission to hospital to date of Discharge from hospital or Death in hospital, whichever comes first, assessed up to 2 years from date of admission.
Secondary Outcomes (4)
Duration of hospital stay
From date of admission to hospital to date of Discharge from hospital or Death in hospital, whichever comes first, assessed up to 2 years from date of admission.
Rate of admission in intensive care unit.
From date of admission to hospital to date of Discharge from hospital or Death in hospital, whichever comes first, assessed up to 2 years from date of admission.
Neurological deficits
From date of admission to hospital to date of Discharge from hospital or Death in hospital, whichever comes first, assessed up to 2 years from date of admission.
Seizures
From date of admission to hospital to date of Discharge from hospital or Death in hospital, whichever comes first, assessed up to 2 years from date of admission.
Study Arms (2)
Retrospective Cohort
Supratentorial/Suprasellar brain tumor patients with Glasgow Coma Score \> 3 at time of admission.
Prospective Cohort
Supratentorial/Suprasellar brain tumor patients with Glasgow Coma Score \> 3 at time of recruitment.
Interventions
Eligibility Criteria
Patients admitted to NIMHANS for surgical management of Supratentorial/Suprasellar tumor management with GCS \> 3 at recruitment (for prospective cohort) or admission (for retrospective cohort).
You may qualify if:
- Patients undergoing surgical management for supratentorial/suprasellar tumors.
You may not qualify if:
- Glasgow Coma Score (GCS) \<4.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor
Study Record Dates
First Submitted
June 14, 2018
First Posted
June 26, 2018
Study Start
December 15, 2013
Primary Completion
April 30, 2014
Study Completion
April 30, 2014
Last Updated
June 26, 2018
Record last verified: 2018-06
Data Sharing
- IPD Sharing
- Will not share